IDiyas

For the Inventor, By the Inventor

Piscataway, NJ, United States of America

Kumar Balashanmuga Pabbisetty

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 9.8

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:

goldMedal11 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal2 out of 36 
 
Bristol-myers Squibb
 patents

Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

13 patents (USPTO):
1. 12428421 - Pyrimidinones as factor XIA inhibitors (2025-09-30),
2. 11053247 - Pyrimidinones as factor XIA inhibitors (2021-07-06),
3. 10829501 - Spiroheptane salicylamides and related compounds as inhibitors of ROCK (2020-11-10),
4. 10611776 - Spiroheptane salicylamides and related compounds as inhibitors of rock (2020-04-07),
5. 10336754 - Pyrimidinones as factor XIa inhibitors (2019-07-02),
6. 10316035 - Triazolopyridine inhibitors of myeloperoxidase (2019-06-11),
7. 10287288 - Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties (2019-05-14),
8. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),
9. 9951071 - Dihydropyridone P1 as factor XIa inhibitors (2018-04-24),
10. 9920075 - Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase (2018-03-20),
11. 9777001 - Macrocycles with aromatic P2' groups as factor xia inhibitors (2017-10-03),
12. 9453018 - Pyrimidinones as factor XIa inhibitors (2016-09-27),
13. 9409908 - Dihydropyridone p1 as factor XIa inhibitors (2016-08-09),

Title: Innovations of Kumar Balashanmuga Pabbisetty in Pharmaceutical Chemistry

Introduction

Kumar Balashanmuga Pabbisetty, based in Piscataway, NJ, is an accomplished inventor with a remarkable portfolio that includes 12 patents. His innovative contributions primarily focus on pharmaceutical compounds that address various medical conditions, showcasing his expertise in the field of pharmaceutical chemistry.

Latest Patents

Among his latest inventions, Pabbisetty has developed compounds characterized as pyrimidinones functioning as selective factor XIa inhibitors. The compounds, represented in his patent, aim to treat thromboembolic and inflammatory disorders, offering new possibilities in therapeutic interventions. He also introduced spiroheptane salicylamides and related compounds that serve as inhibitors of Rho-associated protein kinase (ROCK). This invention paves the way for treatments related to cardiovascular, smooth muscle, oncological, neuropathologic, autoimmune, fibrotic, and inflammatory disorders.

Career Highlights

Kumar Balashanmuga Pabbisetty has gained valuable experience while working at Bristol-Myers Squibb Company, where he contributed significantly to pharmaceutical advancements. His extensive background in research and development in the pharmaceutical industry allows him to create impactful inventions that address pressing health issues.

Collaborations

During his career, Pabbisetty has collaborated with notable professionals such as Andrew K. Dilger and Wu Yang. These partnerships have undoubtedly enhanced his innovative capabilities and the breadth of his research endeavors.

Conclusion

Kumar Balashanmuga Pabbisetty continues to make strides in the realm of pharmaceutical inventions. With his impressive number of patents and dedication to addressing vital medical challenges, he remains a prominent figure in the field, driving forward the development of novel compounds for various disorders. His work demonstrates the essential role that inventors play in advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…